{Reference Type}: Case Reports
{Title}: Eptifibatide-induced acute profound thrombocytopenia: a case report.
{Author}: Graidis C;Golias C;Dimitriadis D;Dimitriadis G;Bitsis T;Dimitrelos I;Tsiakou A;Charalabopoulos K;
{Journal}: BMC Res Notes
{Volume}: 7
{Issue}: 0
{Year}: Feb 2014 25
暂无{DOI}: 10.1186/1756-0500-7-107
{Abstract}: <B>BACKGROUND: </B>The interactions among cells or among cells and components of the extracellular matrix, is a crucial pathophysiological process involving some molecules collectively known as adhesion molecules (CAMs). Glycoprotein IIb / IIIa receptors are only restricted to blood platelets and they bind fibrinogen and adhesion proteins such as fibronectin, vitronectin, von Willebrand factor to form cross bridges between adjacent platelets. IIb/IIIa receptor antagonists are an object of intense research activity for target therapy worldwide during the last decades. Three GPIIb/IIIa inhibitors, abciximab, tirofiban, and eptifibatide, have been approved for clinical use. Profound thrombocytopenia is an uncommon but clinically important complication of glycoprotein IIb/IIIa inhibitors.<BR><B>METHODS: </B>This case report discusses a forty-four-year-old male patient with acute coronary syndrome who underwent percutaneous coronary intervention and developed profound thrombocytopenia within 4 hours of first administration of eptifibatide.<BR><B>CONCLUSIONS: </B>This report adds another case of eptifibatide-induced thrombocytopenia to the medical literature and endorses the importance of platelet count monitoring after initiating therapy with this agent.